These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 17170014)

  • 1. RASSF1A methylation and K-ras and B-raf mutations and recurrent endometrial cancer.
    Pijnenborg JM; Dam-de Veen GC; Kisters N; Delvoux B; van Engeland M; Herman JG; Groothuis PG
    Ann Oncol; 2007 Mar; 18(3):491-7. PubMed ID: 17170014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypermethylation of RAS effector related genes and DNA methyltransferase 1 expression in endometrial carcinogenesis.
    Liao X; Siu MK; Chan KY; Wong ES; Ngan HY; Chan QK; Li AS; Khoo US; Cheung AN
    Int J Cancer; 2008 Jul; 123(2):296-302. PubMed ID: 18404674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RASSF1A hypermethylation and its inverse correlation with BRAF and/or KRAS mutations in MSI-associated endometrial carcinoma.
    Kang S; Lee JM; Jeon ES; Lee S; Kim H; Kim HS; Seo SS; Park SY; Sidransky D; Dong SM
    Int J Cancer; 2006 Sep; 119(6):1316-21. PubMed ID: 16619251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High frequency of RASSF1A and RARb2 gene promoter methylation in morphologically normal endometrium adjacent to endometrioid adenocarcinoma.
    Arafa M; Kridelka F; Mathias V; Vanbellinghen JF; Renard I; Foidart JM; Boniver J; Delvenne P
    Histopathology; 2008 Nov; 53(5):525-32. PubMed ID: 18783461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frequent involvement of ras-signalling pathways in both polypoid-type and flat-type early-stage colorectal cancers.
    Noda H; Kato Y; Yoshikawa H; Arai M; Togashi K; Nagai H; Konishi F; Miki Y
    J Exp Clin Cancer Res; 2006 Jun; 25(2):235-42. PubMed ID: 16918136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Promoter hypermethylation and reduced expression of RASSF1A are frequent molecular alterations of endometrial carcinoma.
    Pallarés J; Velasco A; Eritja N; Santacana M; Dolcet X; Cuatrecasas M; Palomar-Asenjo V; Catasús L; Prat J; Matias-Guiu X
    Mod Pathol; 2008 Jun; 21(6):691-9. PubMed ID: 18469797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frequent silencing of RASSF1A via promoter methylation in follicular thyroid hyperplasia: a potential early epigenetic susceptibility event in thyroid carcinogenesis.
    Brown TC; Juhlin CC; Healy JM; Prasad ML; Korah R; Carling T
    JAMA Surg; 2014 Nov; 149(11):1146-52. PubMed ID: 25229773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Promoter hypermethylation of the tumor-suppressor genes RASSF1A, GSTP1 and CDH1 in endometrial cancer.
    Fiolka R; Zubor P; Janusicova V; Visnovsky J; Mendelova A; Kajo K; Lasabova Z; Plank L; Danko J
    Oncol Rep; 2013 Dec; 30(6):2878-86. PubMed ID: 24068440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas.
    Reifenberger J; Knobbe CB; Sterzinger AA; Blaschke B; Schulte KW; Ruzicka T; Reifenberger G
    Int J Cancer; 2004 Apr; 109(3):377-84. PubMed ID: 14961576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncosuppressor methylation: a possible key role in colon metastatic progression.
    Tommasi S; Pinto R; Petriella D; Pilato B; Lacalamita R; Santini D; Zito F; Colucci G; Paradiso A; Silvestris N
    J Cell Physiol; 2011 Jul; 226(7):1934-9. PubMed ID: 21506124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inverse correlation between RASSF1A hypermethylation, KRAS and BRAF mutations in cervical adenocarcinoma.
    Kang S; Kim HS; Seo SS; Park SY; Sidransky D; Dong SM
    Gynecol Oncol; 2007 Jun; 105(3):662-6. PubMed ID: 17360030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Promoter methylation of RASSF1A and DAPK and mutations of K-ras, p53, and EGFR in lung tumors from smokers and never-smokers.
    Liu Y; Gao W; Siegfried JM; Weissfeld JL; Luketich JD; Keohavong P
    BMC Cancer; 2007 May; 7():74. PubMed ID: 17477876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular profiles of benign and (pre)malignant endometrial lesions.
    van der Putten LJM; van Hoof R; Tops BBJ; Snijders MPLM; van den Berg-van Erp SH; van der Wurff AAM; Bulten J; Pijnenborg JMA; Massuger LFAG
    Carcinogenesis; 2017 Mar; 38(3):329-335. PubMed ID: 28203752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RAS/RAF mutation and defective DNA mismatch repair in endometrial cancers.
    Mutch DG; Powell MA; Mallon MA; Goodfellow PJ
    Am J Obstet Gynecol; 2004 Apr; 190(4):935-42. PubMed ID: 15118616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. K-ras mutations and RASSF1A promoter methylation in colorectal cancer.
    van Engeland M; Roemen GM; Brink M; Pachen MM; Weijenberg MP; de Bruïne AP; Arends JW; van den Brandt PA; de Goeij AF; Herman JG
    Oncogene; 2002 May; 21(23):3792-5. PubMed ID: 12032847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. K-ras point mutations in endometrial carcinoma: effect on outcome is dependent on age of patient.
    Ito K; Watanabe K; Nasim S; Sasano H; Sato S; Yajima A; Silverberg SG; Garrett CT
    Gynecol Oncol; 1996 Nov; 63(2):238-46. PubMed ID: 8910634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concomitant RASSF1A hypermethylation and KRAS/BRAF mutations occur preferentially in MSI sporadic colorectal cancer.
    Oliveira C; Velho S; Domingo E; Preto A; Hofstra RM; Hamelin R; Yamamoto H; Seruca R; Schwartz S
    Oncogene; 2005 Nov; 24(51):7630-4. PubMed ID: 16007118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRAF mutation in endometrial carcinoma and hyperplasia: correlation with KRAS and p53 mutations and mismatch repair protein expression.
    Feng YZ; Shiozawa T; Miyamoto T; Kashima H; Kurai M; Suzuki A; Konishi I
    Clin Cancer Res; 2005 Sep; 11(17):6133-8. PubMed ID: 16144912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High frequency of POLE mutations in synchronous endometrial and ovarian carcinoma.
    Ishikawa M; Nakayama K; Nakamura K; Ono R; Yamashita H; Ishibashi T; Minamoto T; Iida K; Razia S; Ishikawa N; Kyo S
    Hum Pathol; 2019 Mar; 85():92-100. PubMed ID: 30448219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation between hypermethylation of the RASSF2A promoter and K-ras/BRAF mutations in microsatellite-stable colorectal cancers.
    Park HW; Kang HC; Kim IJ; Jang SG; Kim K; Yoon HJ; Jeong SY; Park JG
    Int J Cancer; 2007 Jan; 120(1):7-12. PubMed ID: 17013898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.